These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32978507)

  • 1. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials.
    Sinha B; Ghosal S
    Sci Rep; 2020 Sep; 10(1):15781. PubMed ID: 32978507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Mannucci E; Giaccari A; Gallo M; Targher G; Pintaudi B; Candido R; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Mar; 32(3):529-536. PubMed ID: 35144855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.
    Li YR; Wang CC; Liu CH; Yen CL; Wu VC; Huang EJ; Lee CY; Hsiao CC
    Front Endocrinol (Lausanne); 2024; 15():1420485. PubMed ID: 39280016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B; Ghosal S
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
    Zhou Y; Huang Y; Ji X; Wang X; Shen L; Wang Y
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31822895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
    Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
    BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone.
    Atlı Şekeroğlu Z; Şekeroğlu V; Kontaş Yedier S; İlkun E; Liou LS
    Environ Mol Mutagen; 2021 Feb; 62(2):143-154. PubMed ID: 33496997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
    Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
    Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.
    Pavlova V; Filipova E; Uzunova K; Kalinov K; Vekov T
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):502-507. PubMed ID: 29683100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes.
    Miao S; Dong X; Zhang X; Jing S; Zhang X; Xu T; Wang L; Du X; Xu H; Liu Y
    J Diabetes; 2019 Aug; 11(8):684-689. PubMed ID: 30597747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
    Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
    Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic intervention of coenzyme Q10 and its combination with pioglitazone on the mRNA expression level of adipocytokines in diabetic rats.
    Maheshwari RA; Parmar GR; Hinsu D; Seth AK; Balaraman R
    Life Sci; 2020 Oct; 258():118155. PubMed ID: 32735887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
    Hernandez AV; Usmani A; Rajamanickam A; Moheet A
    Am J Cardiovasc Drugs; 2011; 11(2):115-28. PubMed ID: 21294599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Acta Diabetol; 2014 Feb; 51(1):91-101. PubMed ID: 23851465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.